L 377202

L 377202 is a peptide-drug conjugate (PDC) . L 377202 consists of Doxorubicin (HY-15142A) and a prostate-specific antigen (PSA) -hydrolyzable peptide. L 377202 demonstrates strong inhibitory effects on PSA-secreting prostate cancer cells. L 377202 is promising for research of prostate cancer[1].

Product Specifications

CAS Number

[207395-85-5]

UNSPSC

12352005

Target

Peptide-Drug Conjugates (PDCs) ; Prostaglandin Receptor

Related Pathways

Antibody-drug Conjugate/ADC Related; GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

OC1=C2C([C@H](C[C@@](C(CO)=O)(O)C2)O[C@@]3([H])C[C@@H]([C@H](O)[C@H](C)O3)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](CCC(N)=O)NC([C@H](C4CCCCC4)NC([C@H](CO)NC([C@H](C)NC([C@H]5N(C[C@H](O)C5)C(CCCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=C(O)C6=C1C(C7=CC=CC(OC)=C7C6=O)=O

Molecular Formula

C65H89N9O25

Molecular Weight

1396.45

References & Citations

[1]DeFeo-Jones D, et al. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med. 2000 Nov;6 (11) :1248-52.